Participant flow

Mobilization of Stem Cells With Plerixafor, Chemotherapy and G-CSF in Multiple Myeloma or Non-Hodgkin's Lymphoma Patients · Source last updated 2014-03-13

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups

1. description

   Participants with non-Hodgkin's lymphoma were assigned to Plerixafor PM, Plerixafor AM, and Plerixafor After Chemo treatment arms.

   id

   FG000

   title

   Non-Hodgkin's Lymphoma (NHL)

2. description

   Participants with multiple myeloma were assigned to any of the 4 treatment arms.

   id

   FG001

   title

   Multiple Myeloma (MM)

periods

1. drop Withdraws

   1. reasons

      1. group Id

         FG000

         num Subjects

         0

      2. group Id

         FG001

         num Subjects

         1

      type

      Adverse Event

   milestones

   1. achievements

      1. comment

         Plerixafor PM=7, Plerixafor AM=6, Low CD34+ Count/Plerixafor PM=0, and Plerixafor After Chemo=1

         group Id

         FG000

         num Subjects

         14

      2. comment

         Plerixafor PM=12, Plerixafor AM=9, Low CD34+ Count/Plerixafor PM=1, and Plerixafor After Chemo=4

         group Id

         FG001

         num Subjects

         26

      type

      STARTED

   2. achievements

      1. comment

         Completed refers to completed all treatment visits.

         group Id

         FG000

         num Subjects

         14

      2. comment

         Completed refers to completed all treatment visits.

         group Id

         FG001

         num Subjects

         25

      type

      COMPLETED

   3. achievements

      1. group Id

         FG000

         num Subjects

         0

      2. group Id

         FG001

         num Subjects

         1

      type

      NOT COMPLETED

   title

   Treatment Period

2. drop Withdraws

   1. reasons

      1. group Id

         FG000

         num Subjects

         1

      2. group Id

         FG001

         num Subjects

         3

      type

      Final assessment not done

   2. reasons

      1. group Id

         FG000

         num Subjects

         1

      2. group Id

         FG001

         num Subjects

         0

      type

      Death

   milestones

   1. achievements

      1. comment

         Participants who had transplants

         group Id

         FG000

         num Subjects

         14

      2. comment

         Participants who had transplants. One participant did not complete therapy but had a transplant.

         group Id

         FG001

         num Subjects

         26

      type

      STARTED

   2. achievements

      1. comment

         Follow-up visit 12 months post-transplant

         group Id

         FG000

         num Subjects

         12

      2. comment

         Follow-up visit 12 months post-transplant

         group Id

         FG001

         num Subjects

         23

      type

      COMPLETED

   3. achievements

      1. group Id

         FG000

         num Subjects

         2

      2. group Id

         FG001

         num Subjects

         3

      type

      NOT COMPLETED

   title

   Follow-up Period

pre Assignment Details

Forty-four participants were enrolled; four participants never received plerixafor treatment so are excluded from summary tables.

recruitment Details

Patients with NHL or MM eligible for the study were recruited from 5 centers in the United States. The first patient was enrolled (signed informed consent) in April 2004 and the last patient's last study visit was July 2006.

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice